Cargando…

Efficacy of Galium-68 DOTATATE PET/CT in the Detection of Metastasis Rate of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors

OBJECTIVE(S): The aim of this study was to determine metastasis rate in patients with well-differentiated grade1 (G1) and grade 2 (G2) gastroenteropancreatic neuroendocrine tumors (GEP NETs) using the gallium-68 DOTATATE positron emission tomography/computed tomography ((68)Ga-DOTATATE PET/CT). This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Komek, Halil, Ansal Balci, Tansel, Can, Canan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mashhad University of Medical Sciences 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661313/ https://www.ncbi.nlm.nih.gov/pubmed/31380453 http://dx.doi.org/10.22038/AOJNMB.2019.13348

Ejemplares similares

Testicular Metastasis of Jejunal Neuroendocrine Tumor on (68)Ga-DOTATATE PET/CT
por: Şahin, Ömer Faruk, et al.
Publicado: (2023)

Clinical and Prognostic Value of PET/CT Imaging with Combination of (68)Ga-DOTATATE and (18)F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms
por: Zhang, Panpan, et al.
Publicado: (2018)

Ileal Neuroendocrin Tumor Metastasis to Breast Diagnosed with Ga-68 DOTATATE PET/CT
por: Sağlampınar Karyağar, Sevda, et al.
Publicado: (2019)

FAPI-04 Uptake in Healthy Tissues of Cancer Patients in (68)Ga-FAPI-04 PET/CT Imaging
por: Gündoğan, Cihan, et al.
Publicado: (2021)

Dual [(68)Ga]DOTATATE and [(18)F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score
por: Chan, David L., et al.
Publicado: (2022)

Concomitant lung and gastroenteropancreatic neuroendocrine tumors and the value of gallium-68 PET/CT
por: Kaemmerer, Daniel, et al.
Publicado: (2011)

Widespread micronodular hepatic metastases of neuroendocrine tumor detected by [(68)Ga]DOTATATE PET/CT
por: D'Souza, Julia C., et al.
Publicado: (2022)

Striking Visualization of Diffuse Congenital Nesidioblastosis on Ga-68 DOTATATE PET/CT
por: Canbaz, Fevziye, et al.
Publicado: (2019)

Identification and characterization of myocardial metastases in neuroendocrine tumor patients using 68Ga-DOTATATE PET-CT
por: Kunz, Wolfgang G., et al.
Publicado: (2018)

Diagnosing microscopic pancreatic neuroendocrine tumor using 68-Ga-DOTATATE PET/CT: case series
por: Barrio, Martin, et al.
Publicado: (2018)

Prognostic value of a three-scale grading system based on combining molecular imaging with (68)Ga-DOTATATE and (18)F-FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias
por: Karfis, Ioannis, et al.
Publicado: (2020)

Metastatic urinary bladder paraganglioma on Ga-68 DOTATATE PET/CT
por: Ko, Andrew, et al.
Publicado: (2021)

(68)Ga DOTATATE Uptake in Hemangioma Simulating Metastasis on PET Imaging: CT helps characterize bone hemangioma that could be wrongly interpreted as skeletal metastases on (68)Ga DOTATATE PET imaging
por: Vertenten, Bart, et al.
Publicado: (2019)

A Case with (68)Ga-FAPI Positive and (18)F-FDG Negative Breast Cancer
por: Kömek, Halil, et al.
Publicado: (2021)

Unusual Increased Blood Pool Activity on (68)Ga-DOTATATE PET/CT in a Patient With Metastatic Neuroendocrine Disease
por: Sharma, Akash, et al.
Publicado: (2022)

(68)Ga-DOTATATE PET/CT versus (111)In-octreotide scintigraphy in patients with neuroendocrine tumors: a prospective study
por: Cavicchioli, Marcelo, et al.
Publicado: (2022)

Comparison of the application of (18)F-FDG and (68)Ga-DOTATATE PET/CT in neuroendocrine tumors: A retrospective study
por: Hu, Xianwen, et al.
Publicado: (2023)

Role of Combined (68)Ga DOTA-Peptides and (18)F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Kaewput, Chalermrat, et al.
Publicado: (2022)

Ga-68 DOTATATE PET/CT in a patient with Zollinger-Ellison syndrome
por: Jayasekera, Migara, et al.
Publicado: (2023)

Gastrointestinal neuroendocrine tumor with discordant metastatic disease on 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT
por: Resch, Katrin, et al.
Publicado: (2022)

Paget’s Disease Mimicking Bone Metastasis in a Patient with Neuroendocrine Tumor on (68)Ga-DOTANOC PET/CT
por: Gezer, Naciye Sinem, et al.
Publicado: (2016)

[68Ga]-DOTATATE PET/CT and PET/MRI in the diagnosis and management of esthesioneuroblastoma: illustrative cases
por: Roytman, Michelle, et al.
Publicado: (2021)

Incidental primary breast cancer detected on surveillance (68)Ga-DOTATATE PET/CT in a patient with metastatic neuroendocrine carcinoma
por: Ambinder, Emily B., et al.
Publicado: (2020)

Evaluation of (18)F-AlF-NOTA-octreotide for imaging neuroendocrine neoplasms: comparison with (68)Ga-DOTATATE PET/CT
por: Hou, Jiale, et al.
Publicado: (2021)

Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [(68)Ga]Ga DOTATATE PET-CT
por: Bilen, Mehmet Asim, et al.
Publicado: (2022)

Diagnostic challenges in a patient with an occult insulinoma:(68 )Ga‐DOTA‐exendin‐4 PET/CT and (68)Ga‐DOTATATE PET/CT
por: Bongetti, Elisa, et al.
Publicado: (2018)

Galium
por: Phares, D. L.
Publicado: (1868)

Prospective comparison of [(18)F]AlF-NOTA-octreotide PET/MRI to [(68)Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients
por: Boeckxstaens, Lennert, et al.
Publicado: (2023)

(68)Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer
por: Walker, Ronald, et al.
Publicado: (2017)

SUN-314 Gallium-68 DOTATATE PET/CT for Preoperative Localization of Metastatic Insulinoma
por: Bratman, Russell, et al.
Publicado: (2019)

Intra-individual qualitative and quantitative comparison of [(68)Ga]Ga-DOTATATE PET/CT and PET/MRI
por: Lens, Géraldine, et al.
Publicado: (2023)

Diagnostic Efficiency of (68)Ga-DOTATATE PET/CT as Compared to (99m)Tc-Octreotide SPECT/CT and Conventional Morphologic Modalities in Neuroendocrine Tumors
por: Fallahi, Babak, et al.
Publicado: (2019)

Tumour-to-liver ratio determined by [(68)Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours
por: Kim, Yong-il, et al.
Publicado: (2020)

The Role of Pre-ablative Stimulated Thyroglobulin and Thyroglobulin/ Thyroid-Stimulating Hormone Ratio for Predicting Metastasis in Thyroid Cancer
por: Demir, Fadime, et al.
Publicado: (2019)

MON-499 Tumor Induced Osteomalacia: (68)Ga-DOTATATE PET/CT Scan For Localization
por: Thangavelu, Thiyagarajan, et al.
Publicado: (2019)

Ga-68 DOTATATE PET/CT in the Evaluation of Paragangliomas and Other Indeterminate Lesions in the Head and Neck
por: Kuker, Russ, et al.
Publicado: (2022)

The Diagnostic and Grading Accuracy of (68)Ga-DOTATATE and (18)F-FDG PET/MR for Pancreatic Neuroendocrine Neoplasms
por: Zhou, Jinxin, et al.
Publicado: (2022)

Long-Term Survival and Value of (18)F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with (177)Lu-DOTATATE
por: Rodrigues, Margarida, et al.
Publicado: (2021)

A personal acquisition time regimen of (68)Ga-DOTATATE total-body PET/CT in patients with neuroendocrine tumor (NET): a feasibility study
por: Xiao, Jie, et al.
Publicado: (2022)

Comparison of (18)F‐FDG PET/CT and (68)Ga‐DOTATATE PET/CT in the Targeted Imaging of Culprit Tumors Causing Osteomalacia
por: Yu, Hao‐nan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dh7gmes53nsoecoq0govu1hro1